The records describe four separate proposed securities class actions announced Aug. 21, 2026, with no class certified in the proceedings. Robbins LLP set an Oct. 5, 2026, deadline for investors in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities acquired from March 9 through June 24, 2026, alleging overly positive disclosures about the expected timing of expanded CVS Caremark coverage for neffy, a needle-free epinephrine nasal spray. ARS later said CVS Caremark reserved its decision until January 2027; the release reported a stock decline from $10.54 on June 24, 2026, to $8.02 on June 25, 2025, or more than 23.9%, with the dates and percentage stated as reported. The same firm set an Oct. 5 deadline for sellers of Smartsheet Inc. (NYSE: SMAR) common stock from June 1 through Sept. 23, 2024, alleging Smartsheet repurchased 1,128,000 shares for approximately $50 million while withholding credible acquisition proposals from Blackstone Inc. and Vista Equity Partners Management. Robbins Geller Rudman & Dowd LLP set an Oct. 20 deadline for AEVEX Corp. (NYSE: AVEX) investors who bought shares in or traceable to its April 2026 IPO or between April 17 and June 4, 2026, alleging the company concealed a plan to waive Madison Dearborn Partners LLC’s 180-day lock-up and permit an eight-million-share secondary offering. Rosen Law Firm set an Oct. 13 deadline for Aardvark Therapeutics Inc. (NASDAQ: AARD) investors who bought stock issued in or traceable to its Feb. 13, 2025, IPO or securities between Feb. 13, 2025, and May 14, 2026, alleging misleading disclosures about ARD-101’s safety and clinical, regulatory and commercial prospects. Investors generally need not become lead plaintiffs to potentially share in recoveries.